SCHEDULE: Activist Investor Value Base Halts Campaign Against Perion Network, Citing Persistent Concerns Over Capital Structure and Governance

Activist investor Value Base has ceased its active campaign against Perion Network Ltd., welcoming the removal of the company's rights plan but reiterating significant concerns regarding its capital structure, acquisition strategy transparency, and executive compensation.

Summary

• Value Base Fund Limited Partnership (VBF LP) has filed an Amendment No. 2 to its Schedule 13D regarding its stake in Perion Network Ltd.
• VBF LP, along with Value Base Ltd., Ido Nouberger, and Victor Shamrich, beneficially owns 2,528,710 Ordinary Shares of Perion Network Ltd., representing approximately 5.61% of the outstanding shares.
• The filing indicates that VBF LP sent an 'Additional Letter' to Perion's Board of Directors on July 14, 2025.
• VBF LP welcomed Perion's decision to remove its previously adopted rights plan (Poison Pill), though it noted the decision was made 'blatantly late and after damage had already been caused'.
• The activist investor highlighted several ongoing concerns for the Board to address, including an inefficient capital structure, lack of transparent growth strategy (especially regarding acquisitions), and the scope and structure of senior management compensation.
• VBF LP stated that, commencing July 14, 2025, it does not intend to take any additional active measures against the Board or management and no longer insists on convening a Shareholders Meeting.
• As of March 31, 2025, Perion Network Ltd. had approximately $359 million in material excess net cash on its balance sheet.
• Value Base Fund General Partner Ltd. (VBF GP) sold 17,069 shares at $11.23 on July 11, 2025, and 51,052 shares at $11.25 on July 10, 2025, both on Nasdaq.

Sentiment

Score: 5

Explanation: The sentiment is mixed. While the activist investor is stepping back from active measures and welcomes the removal of the 'Poison Pill', they continue to highlight significant, unaddressed concerns regarding the company's capital structure, acquisition transparency, and executive compensation, indicating underlying issues persist.

Positives

• Perion Network Ltd. removed its previously adopted rights plan (Poison Pill).
• Activist investor Value Base Fund Limited Partnership (VBF LP) has stated it will no longer take active measures against Perion's Board or management.
• VBF LP has withdrawn its demand for a special general meeting of shareholders.

Negatives

• Value Base Fund Limited Partnership (VBF LP) believes the removal of the Poison Pill was 'blatantly late and after damage had already been caused'.
• VBF LP asserts that Perion's capital structure is inefficient and significantly impairs value generation, citing approximately $359 million in excess net cash as of March 31, 2025.
• VBF LP believes the existing share repurchase program is insufficient given the large amount of excess cash.
• VBF LP criticizes the lack of a sufficiently transparent and clear growth strategy, particularly concerning acquisition activity and post-transaction reporting.
• VBF LP states that the scope of compensation for senior management is too high, especially in light of the company's and stock's performance, and that the existing compensation structure does not create proper incentives.

Risks

• Inefficient capital structure, characterized by significant excess cash, may lead to low return on capital and raise investor concerns about future fund utilization.
• Lack of transparency in the company's acquisition strategy and post-transaction reporting could lead to suboptimal acquisitions and shareholder distrust.
• A compensation policy for senior management that is perceived as excessive or misaligned with company performance could erode shareholder and investor confidence.

Future Outlook

Value Base Fund Limited Partnership (VBF LP) has indicated that it will not take any additional active measures against Perion Network Ltd.'s Board of Directors or management, and no longer insists on convening a special general meeting of shareholders, following the cancellation of the company's rights plan.

Management Comments

• Value Base Fund Limited Partnership (VBF LP) welcomed Perion's decision to remove the rights plan, stating it was 'blatantly late and after damage had already been caused to the Company's shareholders'.
• VBF LP believes Perion's capital structure is inefficient and 'impairs heavily on the ability to generate substantial value for the shareholders', noting approximately $359 million in excess net cash.
• VBF LP stated that the existing share repurchase program is 'not sufficient in itself' and that there is 'room to examine a significant additional return of capital to shareholders'.
• VBF LP believes that acquisitions activity should be conducted with 'a greater level of transparency both at the strategic level and at the post-transaction reporting level'.
• VBF LP stated that the scope of compensation for senior management is 'too high, particularly in light of the performance of the Company and its stock', and that the existing compensation structure 'does not create a proper and balanced incentive for management'.

Industry Context

This filing reflects ongoing trends in shareholder activism, where investors leverage their stakes to influence corporate governance, capital allocation, and strategic direction. Value Base's campaign against Perion Network Ltd. highlights common activist themes such as optimizing capital structure (e.g., returning excess cash to shareholders), demanding greater transparency in M&A activities, and scrutinizing executive compensation, all aimed at enhancing shareholder value. The resolution of the activist campaign, with the investor stepping back after some demands are met, is a typical outcome in such engagements.

Comparison to Industry Standards

• The activist's critique of Perion's 'inefficient capital structure' with $359 million in excess net cash suggests a deviation from optimal capital allocation practices common in the technology and ad-tech sectors, where companies often reinvest heavily in growth or return capital efficiently to shareholders. While specific comparable companies are not named, the implication is that Perion's cash levels are unusually high relative to its operating value, potentially underperforming peers in terms of return on capital.
• The demand for 'greater transparency' in acquisition activity, including disclosure of 'valuation multiples' and 'management's projections', aligns with best practices for M&A reporting, particularly for publicly traded companies. The criticism regarding the Greenbids acquisition disclosure implies Perion's practices fell short of industry standards for investor communication on strategic transactions.
• Concerns about 'excessive' and misaligned 'compensation policy' for senior management are common in corporate governance discussions. While no specific benchmarks are provided, the activist's stance suggests Perion's executive pay structure may not be competitive or aligned with performance metrics seen in comparable companies within the ad-tech or software industry, where performance-based incentives are typically emphasized.

Corporate Governance

Stakeholder Impact

• Shareholders: The removal of the Poison Pill is generally positive for shareholders as it reduces anti-takeover defenses. However, the activist's concerns about inefficient capital structure, lack of transparency, and compensation policy suggest potential negative impacts on shareholder value if not addressed. The activist stepping back may reduce immediate pressure but leaves underlying issues.
• Management: Management faces continued scrutiny regarding capital allocation, acquisition strategy, and compensation, despite the activist stepping back from active measures. The activist's comments imply a need for management to improve transparency and align compensation with performance.

Next Steps

• Perion Network Ltd.'s Board of Directors is urged by Value Base Fund Limited Partnership to consider addressing concerns regarding the company's capital structure, growth strategy transparency, and senior management compensation policy.
• Value Base Fund Limited Partnership will not take additional active measures against Perion's Board or management.

Key Dates

Keywords

Perion Network Ltd., Value Base, Schedule 13D, Activist Investor, Corporate Governance, Capital Structure, Executive Compensation, Acquisition Strategy, Poison Pill, Shareholder Activism, SEC Filing